I. Goncalves

发表

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.

N. Johnson, A. Santoro, P. Zinzani, 2021, The Lancet. Oncology.

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.

M. Beksac, M. Dimopoulos, S. Lonial, 2020, The Lancet. Oncology.

Risk factors for indications of intraoperative blood transfusion among patients undergoing surgical treatment for colorectal adenocarcinoma.

J. Bordin, D. Matos, M. Linhares, 2009, Arquivos de gastroenterologia.

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

N. Johnson, A. Santoro, P. Zinzani, 2020, Journal of Clinical Oncology.